Fig. 5: Tumor secretory cDC2 are associated to good prognosis in inflamed cancers and to response to immunotherapy. | Nature Communications

Fig. 5: Tumor secretory cDC2 are associated to good prognosis in inflamed cancers and to response to immunotherapy.

From: PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity

Fig. 5

A Survival analysis among patients expressing high (black) and low (gray) levels of the 36-gene tumor secretory cDC2 signature (left) and T cell signature (center) (cutoff at median, log-rank test), among 500 non-metastatic HNSCC patients from The Cancer Genome Atlas (TCGA). Right: Pearson correlation between the 2 signatures in the same dataset. Line represents linear regression; grey zone represents 95% confidence interval. p-value is for two-sided statistical analysis. B Survival analysis as in A left for 318 triple negative breast cancer (TNBC) patients (left) and 1407 luminal breast cancer (LumBC) patients (right) from METABRIC dataset24. A, B: HR hazard ratio, NS not significant. C Tumor secretory cDC2 signature expression among responders and non-responders melanoma patients treated by immune checkpoint blockade from previous studies27 (left) and28 (right), two-sided Mann–Whitney tests.

Back to article page